Key Highlights

  • Envista Holdings (NYSE:NVST) posted USD 3.11 of diluted EPS against a USD 0.18 loss, helped by a USD 428.1 million non-cash translation gain tied to Legal entity dissolutions.
  • Cytek Biosciences (NASDAQ:CTKB) lifted gross Margin to 59% from 53% on USD 53.2 million of revenue, yet still posted a USD 6.1 million net loss.
  • Alpha Teknova (NASDAQ:TKNO) grew Revenue 22% to USD 12.7 million and completed a USD 46.0 million offering that closed on October 22, 2026.
  • Adaptive Biotechnologies (NASDAQ:ADPT) delivered 39,587 clonoSEQ tests, up 46%, while total revenue slid to USD 83.9 million.

Envista Holdings (NYSE:NVST): A Non-Cash Translation Gain Sits Behind the USD 3.11 EPS

Envista Holdings (NYSE:NVST) filed its Quarterly Report on November 4, 2026, covering the quarter that closed October 2. Diluted EPS landed at USD 3.11, compared with a USD 0.18 loss, and Net Income reached USD 508.3 million against a USD 30.3 million loss. The filing explains that winding down certain legal entities forced a cumulative currency translation gain of USD 428.1 million into current earnings. Management describes the item as non-cash and nontaxable. Removing it, our own arithmetic leaves net income near USD 80.2 million, or roughly USD 0.49 a diluted share. Sales increased 3.2% to USD 691.5 million, and core sales expanded 2.7%, made up of a 1.8% price contribution and a 0.9% Volume contribution. Gross margin widened to 57.9% from 55.3%, aided by USD 15.6 million of Tariff refunds. By our reading, part of that margin gain will not repeat, since it rests partly on those refunds. The company bought back 385,748 shares for roughly USD 10.0 million and retains about USD 272.9 million of authorization. No adjusted Earnings figure appears in the material reviewed, and no outlook is given.

Cytek Biosciences (NASDAQ:CTKB): Gross Margin Improves While Litigation Spending Rises

On November 4, 2026, Cytek Biosciences (NASDAQ:CTKB) put its three-month results ending September 30 on file. The firm builds full spectrum flow cytometry instruments, reagents and analysis software used in research and clinical cell work. Revenue grew 2% to USD 53.2 million, with services up 13% to USD 16.1 million and product sales down 3% to USD 37.2 million. Gross margin reached 59% from 53%, reflecting lower overhead, materials and tariff expenses. Operating outlays rose from USD 36.7 million to USD 39.6 million, with general and administrative costs of USD 18.4 million, a 14% jump tied mostly to litigation, doing most of the lifting. The net loss came in at USD 6.1 million, or USD 0.05 a share, compared with USD 5.5 million a year earlier. Cash, restricted cash and marketable securities totaled USD 256.3 million at September 30, 2026, versus USD 261.5 million at the prior year end. Management believes existing cash plus expected operating inflows will cover at least 12 months. Key risks include litigation expense, tariff policy and reliance on distributors outside the United States, and the extract contained no guidance.

Alpha Teknova (NASDAQ:TKNO): A Second Record Quarter Precedes a USD 46.0 Million Share Sale

Alpha Teknova (NASDAQ:TKNO) published third-quarter 2026 numbers on November 4, 2026. The Hollister, California Business produces reagents including agar plates, culture media and buffers that serve drug discovery, Vaccine work and molecular diagnostics. Sales climbed 22%, reaching USD 12.7 million, a figure management described as a second consecutive record. Clinical Solutions jumped 86% to USD 3.2 million, and gross margin improved to 38.0% from 30.7%, while the net loss narrowed to USD 3.5 million. The company sold 9,200,000 shares at USD 5.00 each, raising USD 46.0 million gross, with the transaction closing on October 22, 2026. Issuing Equity adds cash but enlarges the share count, so per-share results get divided across more shares. Before the raise, the quarter-end balance of cash and short-term investments was USD 16.6 million, set against USD 13.2 million of borrowings. For calendar 2026, management now expects sales between USD 46 million and USD 48 million, plus a Free Cash Outflow under USD 8 million. Management views firmer custom product orders as a possible early signal of improving biotech funding, though that remains an opinion rather than a measured trend.

Adaptive Biotechnologies (NASDAQ:ADPT): Test Volume Jumps as a Genentech Agreement Ends

Adaptive Biotechnologies (NASDAQ:ADPT) released quarterly numbers on November 4, 2026. Its flagship clonoSEQ assay, cleared by the FDA, detects minimal residual disease in blood cancers. Total revenue slipped 10.7% (calculated) to USD 83.9 million from USD 94.0 million, because the expiring Genentech collaboration no longer contributes USD 33.7 million. Test deliveries rose 46% to 39,587, and MRD revenue advanced 28% to USD 72.6 million. Net income attributable to shareholders was USD 2.9 million, or USD 0.02 per share, versus USD 9.5 million, while adjusted EBITDA dropped to USD 14.3 million from USD 28.0 million. Cash and marketable securities reached USD 386.4 million following USD 345.0 million of 0% convertible notes issued in June 2026. The board is pursuing a split between the MRD and Immune Medicine businesses, and in July it chose to wind down a research-use TCR sequencing service. An accumulated Deficit of USD 1.4 billion and possible future financing are noted risks, and the filing contains no formal guidance.

Where Things Stand

Read side by side, these four reports rest on different drivers. Envista Holdings (NYSE:NVST) shows USD 3.11 of EPS built mostly on a non-cash entry, and calculated net income without it is near USD 80.2 million. Cytek Biosciences (NASDAQ:CTKB) improved margin but still loses money because of litigation spending. Alpha Teknova (NASDAQ:TKNO) grew 22% and updated its guidance while diluting holders through a new share sale. Adaptive Biotechnologies (NASDAQ:ADPT) lost Genentech revenue even though test volume surged 46%. Watch Envista's core sales and China exposure, Cytek's litigation outlays and cash, Teknova's fourth-quarter revenue relative to its new band and the Free Cash Outflow goal, plus any Adaptive separation news. These filings promise nothing about later quarters.